Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Advanced or Metastatic Solid Tumors 2Thymoma 1Solid Tumor 1Sarcoma 1Piebaldism 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Renal Cell Carcinoma (aRCC) 1Advanced Refractory Solid Tumors 1

Interventions

Doxorubicin 26pembrolizumab 24Radiotherapy 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Specimen Handling 14Nivolumab 14Gemcitabine 13Ifosfamide 12Surgical Procedures, Operative 11Biopsy 11Radiation 10X-Rays 8Temozolomide 8Ipilimumab 8pazopanib 7fludarabine 7cabozantinib 7Irinotecan 7tazemetostat 6liposomal doxorubicin 6Trabectedin 6Surveys and Questionnaires 6Phantoms, Imaging 6Blood Specimen Collection 6olaparib 5eribulin 5atezolizumab 5anlotinib 5Vincristine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × envafolimab × 1 year × Clear all
NCT05941325 2026-06-05

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Shanghai 6th People's Hospital

Phase 2 Suspended
20 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡